Cylene Pharmaceuticals

About:

Cylene Pharmaceuticals discovers, develops and commercializes small molecule drugs that target nucleolus and kill cancer cells.

Website: http://www.cylenepharma.com

Twitter/X: signup

Top Investors: Mitsui & Co, Novartis Venture Fund, Morningside Group, Mitsui Global Investment, Celgene

Description:

Cylene Pharmaceuticals, Inc., a biotech pharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs that target nucleolus and kill cancer cells. It offers nucleolus targeting agents, which are small-molecule targeted cancer therapeutic agents for carcinoid/neuroendocrine tumors and pediatric brain tumors; and serine/threonine protein kinase inhibitors. The company also provides pre-clinical stage oral drug candidates. Cylene Pharmaceuticals, Inc. was founded in 1997 as Cyternex, Inc. and changed its name to Cylene Pharmaceuticals, Inc. in October 2003. The company is based in San Diego, California.

Total Funding Amount:

$102M

Headquarters Location:

San Diego, California, United States

Founded Date:

2001-01-01

Contact Email:

info(AT)cylenepharma.com

Founders:

Tom Farrell

Number of Employees:

1-10

Last Funding Date:

2013-01-22

IPO Status:

Private

Industries:

© 2025 bioDAO.ai